Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy

Cancer

Volumn 107, Issue 10, 2006, Pages 2384-2391

  Cooperberg, Matthew R ^a,k   Freedland, Stephen J ^b   Pasta, David J ^a   Elkin, Eric P ^a   Presti, Joseph C ^c,d   Amling, Christopher L ^e   Terris, Martha K ^f,g   Aronson, William J ^h,i   Kane, Christopher J ^a,j   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Prognosis; Prostate neoplasm; Prostatectomy

Indexed keywords

ACCURACY; ADULT; AFRICAN AMERICAN; ARTICLE; CALCULATION; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CAUCASIAN; DATA BASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; UNIVERSITY OF CALIFORNIA SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CARCINOMA; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RESEARCH DESIGN; RISK ASSESSMENT; UNIVERSITIES;

EID: 33751010199     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22262     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713-2719.
3. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977-1984.
4. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20:557-566.
5. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol. 2001;165:1562-1568.
6. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173:1938-1942.
7. Freedland SJ, Amling CL, Dorey F, et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002;60:670-674.
8. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-771.
9. Greene KL, Meng MV, Elkin EP, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). J Urol. 2004;171:2255-2259.
10. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
11. Smith CV, Bauer JJ, Connelly RR, et al. Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J Urol. 2000;164:1964-1967.
12. Khan MA, Han M, Partin AW, Epstein JI, Walsh PC. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology. 2003;62:86-91; discussion 91-92.
13. Freedland SJ, Presti JC, Jr., Kane CJ, et al. Do younger men have better biochemical outcomes after radical prostatectomy? Urology. 2004;63:518-522.
14. Rasiah KK, Stricker PD, Haynes AM, et al. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. Cancer. 2003;98:2560-2565.
15. Khoddami SM, Shariat SF, Lotan Y, et al. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy. BJU Int. 2004;94:42-46.
16. Mitchell JA, Cooperberg MR, Elkin EP, et al. Ability of two pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005;173:1126-1131.
17. Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. J Urol. 2004;171:1393-1401.
18. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715-717.
19. Lotan Y, Shariat SF, Khoddami SM, et al. The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol. 2004;171(6 pt 1):2209-2214.
20. Freedland SJ, Aronson WJ, Csathy GS, et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology. 2003;61:742-747.
21. Patel DA, Presti JC, Jr., McNeal JE, Gill H, Brooks JD, King CR. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol. 2005;23:6157-6162.
22. Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005;174:2191-2196.
23. Sartor O. Endpoints in prostate cancer clinical trials. Urology. 2002;60:101-107; discussion 107-108.
24. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
25. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439.
26. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910-914.
27. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004;172(5 pt 2):S42-S46; discussion S46-S47.
28. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005;23:6992-6998.